RSV Vaccination in Immunocompromised Patients. — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

RSV Vaccination in Immunocompromised Patients. — Stella

Recruiting

Back to RSV Infection trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Austria

Institute of Specific Prophylaxis and Tropical Medicine, CePII, Medical university of Vienna, Vienna

Key details

Phase

Safety & dosing

Sponsor

Medical University of Vienna

Collaborators

GlaxoSmithKline

Enrollment target

~200 participants

Started

September 2024

Primary completion

August 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov